Outcomes of consolidative surgery following enfortumab vedotin plus pembrolizumab for advanced urothelial cancer: A real-world experience.

INTRODUCTION: Enfortumab vedotin plus pembrolizumab (EVP) has emerged as frontline treatment for patients with advanced urothelial carcinoma. Consolidative surgery can be offered to select patients with surgically resectable disease following EVP; however, data on their surgical outcomes remain limited. This study reports the outcomes of consolidative surgery for advanced urothelial carcinoma following EVP. METHODS: In this retrospective study, we included patients with invasive (≥cT2) urothelial bladder cancer (UBC) or high-risk upper tract urothelial carcinoma (UTUC) who underwent consolidative surgery with curative-intent at our center following EVP between 2022 and 2025. Clinical data, perioperative findings, and oncological outcomes were recorded. The primary endpoint was 30-day postoperative complications and secondary outcomes included pathological complete response (ypT0N0), downstaging (

Duke Scholars

Author Michael R Abern Urology

Author Ankeet Shah Urology

Author Christopher Hoimes Medicine, Medical Oncology

Author Alireza Ghoreifi